Microsoft has detailed the major updates to ASP.NET Core arriving as part of last month's .NET 10 release. As reported, this ...
Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback